FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
--	--

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL					
OMB Number:	3235-0287				
Estimated average burden					
hours per response:	0.5				

1. Name and Address of Reporting Person [*] CARE CAPITAL II LLC				<u>A</u>	2. Issuer Name and Ticker or Trading Symbol <u>ACURA PHARMACEUTICALS, INC</u> [ACUR]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner Officer (give title Other (specify								
(Last) (First) (Middle) 47 HULFISH STREET SUITE 310					3. Date of Earliest Transaction (Month/Day/Year) 04/22/2013									belo			below			
(Street) PRINCETON NJ 08542				- 4. lí	4. If Amendment, Date of Original Filed (Month/Day/Year)								Line)	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person						
(City) (State) (Zip)																				
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/			tion	on 2A. Deemed Execution Date,			3. Transa Code (8)	ction	4. Securities Disposed O	red (A) d	or	5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership				
									Code	v	Amount	(A) (D)	^{or} Pri	се	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
Common	Stock			04/22/2	2013	013			s		500,000(1	^{I)} E	\$3	8.02 ⁽²⁾	8,75	8,757,067			See Footnote ⁽³⁾	
Common Stock			04/23/2	2013				s		315,000(4	⁴⁾ E	\$2	2.67 ⁽⁵⁾	8,44	42,067	I		See Footnote ⁽⁶⁾		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	on Date E se (Month/Day/Year) if (I		ecution Date, 1 ny (4. Transaction Code (Instr. 8)		5. Number of becive Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Exercition Da		7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)		De Se (In	Price of erivative ecurity Istr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	y Direct (or Indir (I) (Instr	Ownership	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Title	Amou or Numb of Share	er						
	1. Name and Address of Reporting Person* CARE CAPITAL II LLC																			
(Last) (First) (Middle) 47 HULFISH STREET SUITE 310				_																
(Street) PRINCE	TON	NJ	08	542																
(City)		(State)	(Zij	D)																
1. Name and Address of Reporting Person [*] CARE CAPITAL INVESTMENTS II LP																				
(Last) (First) (Middle) 47 HULFISH STREET SUITE 310																				
(Street) PRINCE	TON	NJ	08	542																
(City)		(State)	(Zij	D)																

1. Name and Address of Reporting Person^*

Care Capital Offshore Investments II LP

(Last)	(First)	(Middle)							
47 HULFISH STREET									
SUITE 310									
(Street)	NU	005 42							
PRINCETON	NJ	08542							
	(Ctata)	(7in)							
(City)	(State)	(Zip)							

Explanation of Responses:

1. The shares were sold as follows: 467,900 by Care Capital Investments II, LP and 32,100 by Care Capital Offshore Investments II, L.P.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$3.27 to \$2.80, inclusive. The reporting person undertakes to provide to Acura Pharmaceuticals, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (5) to this Form 4.

3. Consists of 8,194,873 shares held by Care Capital Investments II, LP and 562,194 shares held by Care Capital Offshore Investments II, L.P. Care Capital II, LLC is the general partner of Care Capital Investments II, LP and Care Capital Offshore Investments II, LP and as a result, Care Capital II, LLC has the ultimate power to vote or direct the vote and to dispose or direct the disposition of such shares. Care Capital II, LLC is managed by three or more members and accordingly none of the managing members is deemed to have voting or dispositive control over the securities.

4. The shares were sold as follows: 294,777 by Care Capital Investments II, LP and 20,223 by Care Capital Offshore Investments II, L.P.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$2.88 to \$2.60, inclusive.

6. Consists of 7,900,096 shares held by Care Capital Investments II, LP and 541,971 shares held by Care Capital Offshore Investments II, L.P. Care Capital II, LLC is the general partner of Care Capital Investments II, LP and Care Capital Offshore Investments II, LP and as a result, Care Capital II, LLC has the ultimate power to vote or direct the vote and to dispose or direct the disposition of such shares. Care Capital II, LLC is managed by three or more members and accordingly none of the managing members is deemed to have voting or dispositive control over the securities.

Care Capital LLC /s/ David R. 04/24/2013 R<u>amsay</u> Care Capital Investments II, LP, By: Care Capital II, LLC, 04/24/2013 Its General Partner /s/ David R. Ramsay. Care Capital Offshore Investments II, LP, By: Care 04/24/2013 Capital II, LLC, Its General

Date

** Signature of Reporting Person

Partner /s/ David R. Ramsay

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.